GP-100 antigen Completed Phase 2 Trials for Stage IV Melanoma / Recurrent Melanoma Treatment

Indications	Status	Purpose	Phase
DBCOND0028660 (Stage IV Melanoma) DBCOND0028662 (Recurrent Melanoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00019448	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	GP-100 antigen (DB14800) Human interleukin-2 (DB14865)